A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)

Completed · Phase 1

Conditions studied: HIV Infections

In brief

To determine the safety, immunogenicity, and optimal dose of rgp120/HIV-1MN octameric V3 peptide vaccine (SynVac) in healthy volunteers. It is likely that the ultimate control of AIDS will depend on the development of safe and effective vaccines against HIV-1. SynVac is a synthetic candidate vaccine based on eight V3-derived peptides attached to a heptalysyl core to form radial octamers. In animal studies, the vaccine appears safe and demonstrates the capability for producing immune responses.

Key facts

Study ID

NCT00000775

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

40

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subjects must have:
• Normal history and physical exam.
• Negative for HIV by ELISA within 6 weeks of immunization.
• CD4 count >= 400 cells/mm3.
• Normal urinalysis.

You may not qualify if…

• Co-existing Condition:
• Subjects with the following conditions are excluded:
• Medical or psychiatric condition or occupational responsibilities that preclude compliance.
• Active syphilis (volunteers are eligible if serology is documented to be a false positive or due to a remote (> 6 months) treated infection).
• Active tuberculosis (volunteers with a positive PPD and normal chest x-ray showing no evidence of TB and not requiring INH therapy are eligible).
• Hepatitis B surface antigenemia.
• Subjects with the following prior conditions are excluded:
• History of immunodeficiency, chronic illness, autoimmune disease, or use of immunosuppressive medications.
• History of anaphylaxis or other serious adverse reactions to vaccines.
• Prior Medication:
• Excluded:
• Live attenuated vaccines within the past 60 days. NOTE: Medically indicated subunit or killed vaccines (e.g., influenza, pneumococcal) are permitted if received at least 2 weeks prior to first immunization.
• Experimental agents within the past 30 days.
• Prior HIV vaccines.
• Prior Treatment:
• Excluded:
• Blood products or immunoglobulin within the past 6 months.
• Identifiable high-risk behavior for HIV infection, including history of injection drug use within the last 12 months prior to enrollment and higher or intermediate risk sexual behavior.

Where it is running

• St Louis Univ School of Medicine — St Louis, Missouri, United States
• Univ of Rochester Med Ctr — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.